Peristaltic Pump for In Vitro Modeling
Pharma Industry Review
by Pharmaceutical Industry Editor
5d ago
The LiveFlow peristaltic pump for in vitro modeling developed by IVTech, represents a significant advancement in the field of tissue engineering, preclinical research, and drug discovery. Providing the capability to simultaneously administer dual flows with high precision and adaptability, LiveFlow serves as an indispensable instrument for researchers aiming to replicate the dynamic physiological environment of human tissues. Peristaltic Pump for In Vitro Modeling IVTech’s LiveFlow is a state-of-the-art peristaltic pump designed for advanced in vitro modeling within incubator environments. Its ..read more
Visit website
Bioreactors for Dynamic In Vitro Models
Pharma Industry Review
by Pharmaceutical Industry Editor
5d ago
IVTech has developed a groundbreaking range of bioreactors for dynamic in vitro models that transcend traditional cell culture limitations to significantly improve the depth and reliability of preclinical data. The cutting-edge LiveBox1, LiveBox2 and MultiDyn bioreactors are developed specifically to enhance the predictability of in vitro models, crucial for simulating human pato-physiological conditions and drug interactions in preclinical studies and drug discovery. The systems support standard cell culture protocols whilst empowering researchers to create dynamic 5D in vitro models with unp ..read more
Visit website
Breakthroughs in Cervical Cancer Research Using Cellendes’ Advanced 3-D Life Hydrogel Products
Pharma Industry Review
by Pharmaceutical Industry Editor
5d ago
A research study has showcased the use of Cellendes’ advanced 3-D Life Hydrogel products in developing an immunocompetent, PDMS-free organ-on-chip model of cervical cancer. Cellendes is excited to share the groundbreaking application of its innovative 3-D Life Hydrogel in a cutting-edge microfluidic platform, as detailed in the recent publication, “Immunocompetent PDMS-Free Organ-on-Chip Model of Cervical Cancer Integrating Patient-Specific Cervical Fibroblasts and Neutrophils” by Elena Kromidas and colleagues (2023) in the Advanced Healthcare Materials journal. A Novel Polydimethylsiloxa ..read more
Visit website
J& J Announces Positive Phase 3 Trial Results for Nipocalimab in gMG
Pharma Industry Review
by Pharmaceutical Industry Editor
1w ago
Johnson & Johnson (NYSE: JNJ) has announced promising outcomes from its Phase 3 Vivacity-MG study, evaluating Nipocalimab in patients with generalized myasthenia gravis (gMG). The study demonstrated that patients treated with Nipocalimab, in combination with standard of care (SOC), experienced significantly greater improvements compared to those receiving placebo plus SOC. These findings were presented at the European Academy of Neurology (EAN) 2024 Congress and are poised for regulatory submissions later this year. Key Findings from the Vivacity-MG Study The double-blind, placebo-controll ..read more
Visit website
3-D Life Hydrogel Used in Novel Microfluidic Platform to Investigate CAR-T Cell Therapy for Solid Tumors
Pharma Industry Review
by Pharmaceutical Industry Editor
2w ago
Cellendes GmbH is pleased to announce that its pioneering 3-D Life Hydrogel has been successfully utilised in a novel microfluidic platform to assess the applicability of CAR-T cell-mediated therapeutic treatments. This research is detailed in the recent publication, “Breast cancer-on-chip for patient-specific efficacy and safety testing of CAR-T cells” by Maulana et al. (2024) in Cell Stem Cell. The study, led by Tengku Ibrahim Maulana and a team of researchers from Eberhard Karls University-Tübingen, Leiden University Medical Center, Universitätsklinikum Würzburg and the Fraunhofer-Institut ..read more
Visit website
GSK’s ADC Blenrep Cuts Risk of Multiple Myeloma Progression by Nearly 50% in Phase III Trial
Pharma Industry Review
by Pharmaceutical Industry Editor
1M ago
British pharma giant GSK has announced positive results from an interim analysis of the DREAMM-8 phase III head-to-head trial evaluating Blenrep (belantamab mafodotin), in combination with pomalidomide plus dexamethasone (PomDex), versus a standard of care, bortezomib plus PomDex, as a second line and later treatment for relapsed or refractory multiple myeloma. These late-breaking data presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (31 May – 4 June) in Chicago, IL, were featured in the official ASCO press programme and simultaneously published in th ..read more
Visit website
Cellendes to Unveil Research for Novel 3D Tissue Bioprinting Hydrogels at WI3R Symposium
Pharma Industry Review
by Pharmaceutical Industry Editor
1M ago
Cellendes GmbH, a leading innovator in 3D cell culture development and tissue engineering technologies, is set to present its latest research at the WI3R Symposium 2024 – the 1st International Conference of the Würzburg Initiative 3R (WI3R). The conference, focused on the 3R principles (Replacement, Reduction, and Refinement) of animal testing in biomedical research, marks the first international gathering organised by the Würzburg Initiative 3R (WI3R). The event will take place at the Rudolf Virchow Center in Würzburg, Bavaria, Germany, from the 5th of June to the 7th of June 2024. Organised ..read more
Visit website
State-of-the-Art Granulation Techniques in 2024
Pharma Industry Review
by Pharmaceutical Industry Editor
1M ago
In the world of pharmaceutical manufacturing, granulation stands as a cornerstone process, pivotal to the production of oral solid dosage forms. In this dynamic sector, L.B. Bohle’s granulation systems represent the zenith of state-of-the-art technological advancement. As the pharmaceutical industry continues to evolve in 2024, the role of granulation technology has become more critical than ever. Solid oral dosage forms constitute over 60% of pharmaceutical products, such as tablets, capsules, and coated tablets. Moreover, the demand for precise granulation in pharmaceutical processes is incr ..read more
Visit website
Sanofi, Formation Bio and OpenAI Forge First-in-class AI Collaboration
Pharma Industry Review
by Pharmaceutical Industry Editor
1M ago
In a forward-thinking move, Sanofi, Formation Bio, and OpenAI have joined forces to harness the power of artificial intelligence in expediting the drug development process. This ambitious collaboration aims to construct sophisticated AI-driven software designed to streamline the creation of new treatments, thereby delivering them to patients with unprecedented efficiency. The tripartite alliance will integrate a wealth of data, cutting-edge software, and finely-tuned AI models to craft bespoke solutions tailored to various stages of the drug development journey. This initiative marks a pioneer ..read more
Visit website
Photorefractor Device for Myopia Research
Pharma Industry Review
by Pharmaceutical Industry Editor
1M ago
The Photorefractor is an innovative device designed to automatically measure the refractive state of the eye of small, alert laboratory animals. This unique device provides fast, objective and bias-free results and is invaluable for myopia research and pharmacology applications. Device for Myopia Research The Photorefractor provides a fully automated, non-invasive method to measure the refractive state in alert animals, ensuring accurate, fast, and reliable results with minimal handling and maintenance requirements. It comes with a fully integrated camera, light source, and provided ..read more
Visit website

Follow Pharma Industry Review on FeedSpot

Continue with Google
Continue with Apple
OR